On this page:OverviewPublicationsResearchersKey papersJournalsOpen accessInstitutions
ScholarIQanswers from OpenAlex

Protein Degradation and Inhibitors

TopicLeading institutions, researchers & key papers

Protein Degradation and Inhibitors is a topic indexed in ScholarIQ from OpenAlex.

What is known about Protein Degradation and Inhibitors?

ScholarIQrecord summary

This cluster of papers focuses on the targeted degradation of specific proteins, particularly through the use of BET bromodomain inhibitors and PROTACs. The research explores the therapeutic potential of this approach, with a focus on histone recognition, small molecule inhibitors, and the role of epigenetic readers in transcriptional regulation. Additionally, it investigates the use of cereblon-dependent degradation and its implications for drug discovery.

How many works does Protein Degradation and Inhibitors have?

ScholarIQindexed works

Protein Degradation and Inhibitors has 133 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

What is the OpenAlex record for Protein Degradation and Inhibitors?

ScholarIQopenalex

The OpenAlex for Protein Degradation and Inhibitors is on the source record.

What are the most-cited papers on Protein Degradation and Inhibitors?

ScholarIQmost cited works
Catalytic in vivo protein knockdown by small-molecule PROTACs
Daniel P. Bondeson, Alina Mares, Ian E. Smith, Eunhwa Ko, Sébastien Campos, Afjal H. Miah, Katie E Mulholland, Natasha Routly, Dennis L. Buckley, Jeffrey L. Gustafson, Nico Zinn, Paola Grandi, Satoko Shimamura, Giovanna Bergamini, Maria Faelth-Savitski, Marcus Bantscheff, Carly S. Cox, Deborah A. Gordon, Ryan R. Willard, John J. Flanagan, Linda Casillas, Bartholomew J. Votta, Willem den Besten, Kristoffer Famm, Laurens Kruidenier, Paul S. Carter, John D. Harling, Ian Churcher, Craig M. Crews
Nature Chemical Biology. 20151,338 CitationsOPEN ACCESS
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Jing Lü, Yimin Qian, Martha Altieri, Hanqing Dong, Jing Wang, Kanak Raina, John Hines, James D. Winkler, Andrew P. Crew, Kevin Coleman, Craig M. Crews
Chemistry & Biology. 20151,155 CitationsOPEN ACCESS
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Daniel P. Bondeson, Blake E. Smith, George M. Burslem, Alexandru D. Buhimschi, John Hines, Saul Jaime‐Figueroa, Jing Wang, Brian D. Hamman, Alexey Ishchenko, Craig M. Crews
Cell chemical biology. 2017918 CitationsOPEN ACCESS
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Kanak Raina, Jing Lü, Yimin Qian, Martha Altieri, Deborah Gordon, Ann Marie Rossi, Jing Wang, Xin Chen, Hanqing Dong, Kam Siu, James D. Winkler, Andrew P. Crew, Craig M. Crews, Kevin Coleman
Proceedings of the National Academy of Sciences. 2016847 CitationsOPEN ACCESS
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
George M. Burslem, Blake E. Smith, Ashton C. Lai, Saul Jaime‐Figueroa, Daniel McQuaid, Daniel P. Bondeson, Momar Toure, Hanqing Dong, Yimin Qian, Jing Wang, Andrew P. Crew, John Hines, Craig M. Crews
Cell chemical biology. 2017685 CitationsOPEN ACCESS

Where is Protein Degradation and Inhibitors research published, and who funds it?

ScholarIQvenues & funding sources

TOP FUNDERS

National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock

How much of the research on Protein Degradation and Inhibitors is open access?

ScholarIQopen access share
87%OPEN ACCESS
Gold
13%
Green
33%
Hybrid
0%
Bronze
40%
Closed
13%

Related on ScholarIQ

470M+ articles · 14-day free trial